Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma—A Systematic Review
Open Access
- 13 January 2026
- journal article
- review article
- Published by MDPI AG in Dermatopathology
- Vol. 13 (1) , 6
Abstract
Cutaneous squamous cell carcinoma (cSCC) is an immunogenic malignancy with variable immune infiltration and inconsistent responses to checkpoint blockade. Tumor-infiltrating lymphocytes (TILs) influence tumor progression and therapeutic outcome, yet their phenotypic and functional diversity across disease contexts remains incompletely understood. This review systematically characterizes the TIL landscape in human cSCC. Following PRISMA 2020 guidelines, PubMed and Embase were searched up to May 2025 and restricted to studies evaluating tumor-infiltrating lymphocytes in human cSCC, using the modified Newcatle–Ottawa score to assess risk of bias. Data were synthesized qualitatively given methodological heterogeneity. 48 studies met inclusion criteria. cSCCs exhibited dense CD3+ infiltrates composed of cytotoxic (CD8+GzmB+, Ki-67+, CD69+) and regulatory (FOXP3+, CCR4+) subsets. Higher CD8+ activity correlated with smaller tumors and longer disease-free survival, whereas FOXP3+ enrichment and TGF-β2 signaling promoted immune evasion. Immunosuppressed patients demonstrated diminished CD8+ density and clonality. Immune modulation with PD-1/PD-L1 blockade, imiquimod, HPV vaccination, or OX40 stimulation enhanced effector function. The cSCC immune microenvironment reflects a balance between cytotoxic and suppressive factors. Harmonizing multimodal immune profiling and integrating spatial context with systemic immune status may advance both prognostic stratification and therapeutic design.Keywords
This publication has 77 references indexed in Scilit:
- Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic MelanomaAmerican Journal of Clinical Dermatology, 2025
- The clinical landscape of HPV vaccination in preventing and treating cutaneous squamous cell carcinomaJEADV Clinical Practice, 2024
- METTL3-mediated HPV vaccine enhances the effect of anti PD-1 immunotherapy to alleviate the development of cutaneous squamous cell carcinomaAnais Brasileiros de Dermatologia, 2023
- Patterns of Tumor-Infiltrating Lymphocytes Used to Distinguish Primary Cutaneous Squamous Cell Carcinomas That MetastasizeJAMA Dermatology, 2023
- Drug Reaction With Eosinophilia and Systemic Symptoms: A Systematic ReviewThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance systemCancer Medicine, 2022
- T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skinCancer Immunology, Immunotherapy, 2018
- PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinomaCancer Immunology, Immunotherapy, 2018
- Cutaneous squamous cell carcinomaJournal of the American Academy of Dermatology, 2018
- Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinomaCancer Immunology, Immunotherapy, 2017